9 years ago
21 April, 2016
Until recently, DEHP was widely used as a plasticiser in PVC plastics, such as footwear, building materials and floor coverings. However, following concerns that this common environmental contaminant can adversely affect male fertility, it was classified as a reproductive toxicant and listed as an endocrine disrupting chemical (EDC). In February 2015, DEHP was banned from general use under EU law in what many saw as a positive move for health and the environment.
However, the European Union’s Regulation on Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) committee agreed yesterday to grant authorisation of plastics containing DEHP in consumer articles made with recycled PVC. This means that DEHP will continue to be used in consumer products and therefore continue to threaten the environment and human health.
The EU’s decision goes against a non-binding resolution by MEPs last November, which called on the European Commission not to approve the applications for authorisation. Companies involved had not adequately demonstrated that the socio-economic benefits of authorisation would outweigh the risks, including male infertility.
DEHP is widespread in the environment and is detected regularly in human body fluids. It has been linked to various health problems, including male infertility and breast cancer (1). Low concentrations of DEHP are oestrogenic. They have been found to increase breast cancer cell proliferation in tissue culture studies (e.g. 2). Allowing continued use of DEHP will contribute further to environmental exposures and potential health risks.
The same EU committee is considering listing DEHP and three other phthalates, DBP, BBP and DIBP. These substances are of very high concern (SVHCs) due to their endocrine disrupting properties and consequent implications for human health. All four phthalates are reproductive toxicants.
Breast Cancer UK strongly urges the committee to vote to list the four phthalates as SVHCs. This would lead to different risk management considerations in the REACH authorisation and restriction processes. The identification is important because, as EDCs for human health, any level of exposure would constitute a risk that would need to be considered. It would mean banning all imported DEHP products and the three other phthalates.
1. López‐Carrillo L. et al. (2010). Exposure to phthalates and breast cancer risk in northern Mexico. Environmental Health Perspectives 118: 539‐544. https://www.ncbi.nlm.nih.gov/pubmed/20368132
2. Chen, F.P. and Chien, M.H. (2014). Lower concentrations of phthalates induce proliferation in human breast cancer cells. Climacteric 17(4): 377‐384. https://www.ncbi.nlm.nih.gov/pubmed/24228746
5 September 2025
Do you ever wonder what impact your food choices have on your health? Beyond the obvious, does choosing organic food make a real difference, especially when it comes to concerns...
Read full story18 March 2025
I am honoured to officially join Breast Cancer UK as an ambassador and using my voice to champion the power of mindful drinking in reducing breast cancer risk. As the...
Read full story1 August 2024
Credit: Thalie Martini, CEO, Breast Cancer UK Every year, the chilling diagnosis of breast cancer devastates the lives of 56, 000 people across the UK. While medical advancements have bolstered...
Read full story15 February 2024
Breast Cancer UK (BCUK) is pleased to welcome our new Ambassador, Michelle Ogundehin. Michelle has been our fantastic supporter over the years, including blog writing and supporting various campaigns we...
Read full story